Starling Oncology, Inc.: cashflow_financing
| Value | {"amount": 17882000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2021-01-01 – 2021-09-30 |
| Status | current |
| Entity | Starling Oncology, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:08:38.724184+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/31cf5c08-fcbc-4fd4-b29c-0525df018921
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001628280-22-029268Retrieved: 2026-08-19T18:08:38.724184+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001799191/cashflow-financing/2021-09-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/31cf5c08-fcbc-4fd4-b29c-0525df018921
History
- no predecessors — first report